Journal of
AIDS and HIV Research

  • Abbreviation: J. AIDS HIV Res.
  • Language: English
  • ISSN: 2141-2359
  • DOI: 10.5897/JAHR
  • Start Year: 2009
  • Published Articles: 283

Full Length Research Paper

Determinant of mortality in HIV infected people on antiretroviral therapy in Southwest Ethiopia

Bedilu Girma Weji
  • Bedilu Girma Weji
  • Department of Anesthesia, College of Health Science and Medicine, Wolaita Sodo University, P. O. Box 138, Wolaita Sodo, SNNR, Ethiopia.
  • Google Scholar


  •  Received: 24 April 2017
  •  Accepted: 29 June 2017
  •  Published: 30 September 2017

References

AIDS Institute (2013). New York. 

View

 

Alemu AW, Sebastián MS (2010). Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob. Health Action 3(1):5398.
Crossref

 

Andreychyn M, Zhyvytsia D (2013). Effect of antiretroviral therapy on survival of HIV/TB-infected patients in Ukraine. Age 34(1):1.
Crossref

 

Assefa T, Wencheko E (2012). Survival analysis of patients under chronic HIV-care and antiretroviral treatment at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Ethiop. J. Health Dev. 26(1):22-29.

 

Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, Ford N, Mills EJ (2011). Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One 6(4):e19261.
Crossref

 

Biadgilign S, Reda AA, Digaffe T (2012). Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: A retrospective cohort study. AIDS Res. Ther. 9(1):15.
Crossref

 

Cavanaugh JS, Shah NS, Cain KP, Winston CA (2012). Survival among Patients with HIV Infection and Smear-Negative Pulmonary Tuberculosis-United States, 1993-2006. PloS one 7(10):e47855.
Crossref

 

Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV (2011). Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365(6):493-505.
Crossref

 

CSA-Ethiopia ICF (2011). 'International: Ethiopia Demographic and Health Survey 2011. 2012', Maryland, USA: Central Statistical Agency of Ethiopia and ICF International Addis Ababa, Ethiopia and Calverton.

 

Federal Democratic Republic of Ethiopia (2012). Country Progress Report on HIV/AIDS Response. In: The Planning Monitoring and Evaluation Directorate of the Federal HIV/AIDS Prevention and Control Office (HAPCO) (ed)). (2012). Addis Ababa. 

 

FMOH (2007). Implementation Guideline for TUBERCULOSIS / HIV Collaborative Activities in Ethiopia. 

View

 

Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Korthuis PT, Moore RD, Napravnik S (2013). Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin. Infect. Dis. 56(8):1174-1182.
Crossref

 

Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, Fox MP, Wood R, Prozesky H, Giddy J (2013). Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 10(4):e1001418.
Crossref

 

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT (2009). Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360(18):1815-1826.
Crossref

 

Ministry of Health (MOH) (2003). Guidelines for use of Antiretroviral drugs in Ethiopia. In: Disease Prevention and Control Department In collaboration with HIV/ AIDS Prevention and Control office (HAPCO) and Drug Administration and Control Authority (D (2003). Addis Ababa. 

 

Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G (2009). Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J. Acquir. Immune Defic. Syndromes 51(1):65.
Crossref

 

Organization WH (2012a). Antiretroviral treatment as prevention (TASP) of HIV and TUBERCULOSIS Programmatic update', Geneva: WHO.

 

Organization WH (2012b). The strategic use of antiretrovirals to help end the HIV epidemic'. World Health Organization.

 

Shaweno D, Worku A (2012). Tuberculosis treatment survival of HIV positive TUBERCULOSIS patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Res. Notes 
Crossref

 

Tsegaye E, Worku A (2011). Assessment of antiretroviral treatment outcome in public hospitals, South Nations Nationalities and Peoples Region, Ethiopia. Ethiop. J. Health Dev. 25(2):102-109.

 

Vitoria M, Granich R, Banda M, Fox MY, Gilks C (2010). Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull. World Health Organ. 88(4):241-241.

 

World Health Organization (WHO) (2005). Demographic and socioeconomic data. J. Biosoc. Science. 
Crossref

 

World Health Organization (WHO) (2012). World AIDS Day 2012: Closing in on global HIV targets. 

View

 

Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Arnould L, Makombe S, Harries AD (2006). Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 20(18):2355-60.
Crossref

 

Zaidi J, Grapsa E, Tanser F, Newell ML, Bärnighausen T (2013). Dramatic increase in HIV prevalence after scale-up of antiretroviral treatment. AIDS 27(14):2301.
Crossref